(Date:12/14/2009)... Patrick Kennedy Joins with State Biotech Leaders ... in Research and Development while Boosting Rhode ... ,, PROVIDENCE, R.I., Dec. 14 /PRNewswire-USNewswire/ ... leaders in research, medicine and biotechnology gathered ... to discuss the importance of medical innovation ...
(Date:12/14/2009)... Calif., Dec. 14 Nektar Therapeutics (Nasdaq: ... has been appointed to serve on its board ... industry leader with over 35 years of experience ... "Dennis brings to Nektar extensive industry perspective at ... Howard W. Robin, President and CEO of Nektar ...
(Date:12/11/2009)... EntreMed, Inc. (Nasdaq: ENMD ), today announced ... from sales of Thalomid® during the third quarter ... In addition, the Company anticipates a decrease ... 2009. The difference in estimated and actual ... in the fourth quarter financial results. ,, (Logo: ...
(Date:12/11/2009)... researchers have observed the "hot electron" effect in a ... the elusive charges using ultra-thin solar cells, opening a ... report in the current online edition of Applied ... solar cells, it generates free electrons in a range ... charges, the electrons must reach the bottom of the ...
Breaking Biology Technology:Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3EntreMed Reports Receipt of Third Quarter Royalty Payment 2Elusive 'hot' electrons captured in ultra-thin solar cells 2... Ltd., a,bio-diagnostics company specializing in glycan biomarkers for ... announced today,entering into a research agreement with Fox ... to develop a new diagnostics blood test for,breast ... with FCCC on this project," stated Dr. Nir,Dotan, ...
... Approval of Genasense in Relapsed/Refractory Patients, BERKELEY ... GNTA ) announced that the Company has completed ... Janet Woodcock, Acting,Director of the Center for Drug ... Administration (FDA). The appeal asks that CDER approve ...
... Calif., Oct. 25 Cell,Genesys, Inc. (Nasdaq: CEGE ... chief executive officer, and Sharon E. Tetlow, senior,vice president ... a,conference call relating to the company,s third quarter financial ... Thursday, November 1,2007, at 2:00 p.m. PT/ 5:00 p.m. ...
Other Biology Technology:Glycominds and Fox Chase Cancer Center Announce a Collaboration to Discover New Cancer Detection Diagnostic Tests 2Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 2Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 3Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 4Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 5Cell Genesys to Webcast Third Quarter 2007 Conference Call 2Human CXCL14/BRAK Affinity Purified Polyclonal Ab...
mIGSF4A Aff Pur PAb...
Human Serpin B5/Maspin Affinity Purified Polyclonal Ab...
geminin, DNA replication inhibitor...
Biology Products:Biology NavigationMedical Navigation